Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Comments Show Support For MCIT Proposed Rule – With Reservations

AdvaMed, MDMA strongly back the Medicare coverage proposal, but want agency to back off codifying a definition for ‘reasonable and necessary’

Executive Summary

Industry groups were cool to parts of the CMS’s proposed Medicare Coverage of Innovative Technology (MCIT) rule dealing with commercial insurance coverage, as well as definitions used in the proposal.

You may also be interested in...



Industry Praises CMS Final MCIT Reimbursement Rule; Urges Biden Team To Implement It

The US Medicare agency issued on 12 January its final MCIT rule allowing instant reimbursement for FDA breakthrough devices – unless the incoming Biden administration blocks it.

Attorneys, Insurers Disagree With Manufacturers On Need For Clinical Evidence For MCIT Coverage

Both insurance group AHIP and the MedPAC group of Medicare advisors are insisting on CMS reimbursement for medical devices only supported by clinical trials. Industry attorneys weigh in.

Biden Signs COVID-19 Relief EO To Expand And Accelerate Testing, Fill PPE Shortages

Under an extensive COVID-19 plan and executive order signed on 21 January, the US president explained how he’ll beef up testing and manufacturing of medtech to fight the virus.

Topics

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel